Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

New drug application for exenatide has been accepted for review

Amylin Pharmaceuticals and Eli Lilly today announced that the New Drug Application for exenatide has been accepted for review by the Food and Drug Administration.

2 Sep 2004

U.S. FDA study shows Canadian drugs to be more expensive

If you think all drugs from Canada are cheaper than U.S. drugs, think again. In the United States, generic drugs - roughly half of all prescriptions - are often cheaper than both Canadian brand-name drugs and Canadian generic drugs, according to a study by the Food and Drug Administration.

29 Aug 2004

New drug application for regulatory approval of exenatide for the treatment of type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for regulatory approval of exenatide.

1 Jul 2004

Way for diabetics to regulate their blood-sugar levels whilst avoiding weight gain

Type 2 diabetics who take two drugs in combination with insulin can effectively regulate their blood-sugar levels without the common side effect of weight gain, according to a new study by researchers at UT Southwestern Medical Center at Dallas.

28 Jun 2004

World is currently facing a twin epidemic of obesity and type 2 diabetes in young people

The global rise in obesity and type 2 diabetes in children and adolescents has led to an urgent call for action by the International Diabetes Federation (IDF).

25 Jun 2004

Novel findings on treatments for childhood obesity and early polycystic ovary syndrome (PCOS) in young girls

New research findings presented this week in New Orleans during ENDO 2004, the 86th Annual Meeting of The Endocrine Society, could help keep kids healthier.

16 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Combination treatment may help type 2 diabetes patients

New research presented by Peter Weissman, M.D., from the University of Miami, at the 64th Annual Scientific Sessions of the American Diabetes Association shows that combination treatment with rosiglitazone maleate and metformin significantly improves certain markers of cardiovascular disease risk in patients with type 2 diabetes compared to metformin alone.

6 Jun 2004

Exenatide shows significant improvements in glucose control for people With type 2 diabetes

Amylin Pharmaceuticals, Inc., and Eli Lilly and Company have presented detailed 30-week data from two of the three pivotal Phase 3 studies of exenatide during a late-breaking session at the American Diabetes Association's (ADA) 64th Scientific Sessions in Orlando, Florida.

5 Jun 2004

Addition of insulin sensitizer provides lipid benefits for patients with type 2 diabetes

Results of three studies show the oral anti-diabetic agent ACTOS (R) (pioglitazone HCl), in combination with a sulfonylurea, metformin or insulin, resulted in triglyceride decreases and high-density lipoprotein (HDL) cholesterol increases that demonstrated statistically significant improvements from baseline.

30 Apr 2004

Study of three treatments of type 2 diabetes in children and teens has begun in US

A clinical study comparing three treatments of type 2 diabetes in children and teens has begun in 12 medical centers and their affiliated sites around the country, HHS Secretary Tommy G. Thompson announced today.

22 Mar 2004